All Research
    PAPER COLCHIMeta-analysis2025

    Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide

    2025 cumulative-dose meta-analysis (31,397 subjects): low-dose colchicine lowered post-treatment hs-CRP (mean difference approximately -0.40 mg/L) in secondary prevention; the largest cardiovascular benefit is linked to on-treatment hs-CRP falling below roughly 2 mg/L.

    Evidence

    —

    Not Rated

    Sample

    —

    subjects

    Duration

    —

    study period

    Journal

    American Journal of Cardiovascular Drugs

    Aug 2025

    03

    Structured Methods

    Study Design
    Meta-analysis
    Sample Size
    Not reported
    Study Duration
    Not reported
    Methodology
    Not reported
    Limitations
    Not reported
    04

    Citations & References

    Cite this paper

    Unknown authors (2025). Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-025-00743-y

    DOI

    10.1007/s40256-025-00743-y

    Source

    Publisher

    Journal

    American Journal of Cardiovascular Drugs

    05

    Indexing

    Biomarkers

    hs-crp
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation